Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts - PubMed (original) (raw)
Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts
L Park et al. Nat Med. 1998 Sep.
Abstract
Accelerated atherosclerosis in patients with diabetes is a major cause of their morbidity and mortality, and it is unresponsive to therapy aimed at restoring relative euglycemia. In hyperglycemia, nonenzymatic glycation and oxidation of proteins and lipids results in the accumulation of irreversibly formed advanced glycation endproducts. These advanced glycation endproducts engage their receptor in cells of the blood vessel wall, thereby activating mechanisms linked to the development of vascular lesions. We report here a model of accelerated and advanced atherosclerosis in diabetic mice deficient for apolipoprotein E. Treatment of these mice with the soluble extracellular domain of the receptor for advanced glycation endproducts completely suppressed diabetic atherosclerosis in a glycemia- and lipid-independent manner. These findings indicate interaction between the advanced glycation endproducts and their receptor is involved in the development of accelerated atherosclerosis in diabetes, and identify this receptor as a new therapeutic target in diabetic macrovascular disease.
Similar articles
- Upregulation of the ligand-RAGE pathway via the angiotensin II type I receptor is essential in the pathogenesis of diabetic atherosclerosis.
Ihara Y, Egashira K, Nakano K, Ohtani K, Kubo M, Koga J, Iwai M, Horiuchi M, Gang Z, Yamagishi S, Sunagawa K. Ihara Y, et al. J Mol Cell Cardiol. 2007 Oct;43(4):455-64. doi: 10.1016/j.yjmcc.2007.07.044. Epub 2007 Jul 21. J Mol Cell Cardiol. 2007. PMID: 17761193 - Advanced glycation end products and receptor-oxidative stress system in diabetic vascular complications.
Yamagishi S. Yamagishi S. Ther Apher Dial. 2009 Dec;13(6):534-9. doi: 10.1111/j.1744-9987.2009.00775.x. Ther Apher Dial. 2009. PMID: 19954478 Review. - RAGE modulates vascular inflammation and atherosclerosis in a murine model of type 2 diabetes.
Wendt T, Harja E, Bucciarelli L, Qu W, Lu Y, Rong LL, Jenkins DG, Stein G, Schmidt AM, Yan SF. Wendt T, et al. Atherosclerosis. 2006 Mar;185(1):70-7. doi: 10.1016/j.atherosclerosis.2005.06.013. Epub 2005 Aug 1. Atherosclerosis. 2006. PMID: 16076470 - The AGE/RAGE axis in diabetes-accelerated atherosclerosis.
Jandeleit-Dahm K, Watson A, Soro-Paavonen A. Jandeleit-Dahm K, et al. Clin Exp Pharmacol Physiol. 2008 Mar;35(3):329-34. doi: 10.1111/j.1440-1681.2007.04875.x. Clin Exp Pharmacol Physiol. 2008. PMID: 18290873 Review.
Cited by
- Microalbuminuria and sRAGE in high-risk hypertensive patients treated with nifedipine/telmisartan combination treatment: a substudy of TALENT.
Falcone C, Buzzi MP, Bozzini S, Boiocchi C, D'Angelo A, Schirinzi S, Esposito C, Torreggiani M, Choi J, Ochan Kilama M, Mancia G. Falcone C, et al. Mediators Inflamm. 2012;2012:874149. doi: 10.1155/2012/874149. Epub 2012 Feb 13. Mediators Inflamm. 2012. PMID: 22474401 Free PMC article. Clinical Trial. - Diabetes with poor glycaemic control does not promote atherosclerosis in genetically modified hypercholesterolaemic minipigs.
Al-Mashhadi RH, Bjørklund MM, Mortensen MB, Christoffersen C, Larsen T, Falk E, Bentzon JF. Al-Mashhadi RH, et al. Diabetologia. 2015 Aug;58(8):1926-36. doi: 10.1007/s00125-015-3637-1. Epub 2015 May 31. Diabetologia. 2015. PMID: 26026653 - Hyperglycemia and endothelial dysfunction in atherosclerosis: lessons from type 1 diabetes.
Funk SD, Yurdagul A Jr, Orr AW. Funk SD, et al. Int J Vasc Med. 2012;2012:569654. doi: 10.1155/2012/569654. Epub 2012 Feb 14. Int J Vasc Med. 2012. PMID: 22489274 Free PMC article. - Cilostazol attenuates the severity of peripheral arterial occlusive disease in patients with type 2 diabetes: the role of plasma soluble receptor for advanced glycation end-products.
Liu JS, Chuang TJ, Chen JH, Lee CH, Hsieh CH, Lin TK, Hsiao FC, Hung YJ. Liu JS, et al. Endocrine. 2015 Aug;49(3):703-10. doi: 10.1007/s12020-015-0545-6. Epub 2015 Feb 11. Endocrine. 2015. PMID: 25666934 Free PMC article. Clinical Trial. - Preserved DNA Damage Checkpoint Pathway Protects against Complications in Long-Standing Type 1 Diabetes.
Bhatt S, Gupta MK, Khamaisi M, Martinez R, Gritsenko MA, Wagner BK, Guye P, Busskamp V, Shirakawa J, Wu G, Liew CW, Clauss TR, Valdez I, El Ouaamari A, Dirice E, Takatani T, Keenan HA, Smith RD, Church G, Weiss R, Wagers AJ, Qian WJ, King GL, Kulkarni RN. Bhatt S, et al. Cell Metab. 2015 Aug 4;22(2):239-52. doi: 10.1016/j.cmet.2015.07.015. Cell Metab. 2015. PMID: 26244933 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources